Niels Wcj van de Donk

42PUBLICATIONS
169CO-AUTHORS
Haematological tumoursMedical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Sep 01, 2026
Spatial profiling identifies a distinct and topographically-defined tumor microenvironment that emerges during multiple myeloma evolution.

|Apr 20, 2026
Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma.

|Apr 06, 2026
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Francesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos

|Feb 20, 2026
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab.

Febe Smits, Kaz Groen, Charlotte L B M Korst

|Jan 04, 2026
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort.

Thomas G Martin, María-Victoria Mateos, Jun Ho Yi

|Nov 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network.

Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel

Pageof 7

Frequent Collaborators

9 joint publications

Sonja Zweegman

5 joint publications

Charlotte L B M Korst

5 joint publications

Christie P M Verkleij

4 joint publications

Wassilis S C Bruins